Amyloid formation disrupts the balance between interleukin-1β and interleukin-1 receptor antagonist in human islets

Mol Metab. 2017 May 31;6(8):833-844. doi: 10.1016/j.molmet.2017.05.016. eCollection 2017 Aug.

Abstract

Objectives: β-cell dysfunction and apoptosis associated with islet inflammation play a key role in the pathogenesis of type 2 diabetes (T2D). Growing evidence suggests that islet amyloid, formed by aggregation of human islet amyloid polypeptide (hIAPP), contributes to islet inflammation and β-cell death in T2D. We recently showed the role of interleukin-1β (IL-1β)/Fas/caspase-8 apoptotic pathway in amyloid-induced β-cell death. In this study, we used human islets in culture as an ex vivo model of amyloid formation to: (1) investigate the effects of amyloid on islet levels of the natural IL-1 receptor antagonist (IL-1Ra); (2) examine if modulating the IL-1β/IL-1Ra balance can prevent amyloid-induced β-cell Fas upregulation and apoptosis.

Methods: Isolated human islets (n = 10 donors) were cultured in elevated glucose (to form amyloid) with or without a neutralizing human IL-1β antibody for up to 7 days. Parallel studies were performed with human islets in which amyloid formation was prevented by adeno-siRNA-mediated suppression of hIAPP expression (as control). β-cell levels of IL-1Ra, Fas, apoptosis as well as islet function, insulin- and amyloid-positive areas, and IL-1Ra release were assessed.

Results: Progressive amyloid formation in human islets during culture was associated with alterations in IL-1Ra. Islet IL-1Ra levels were higher at early stages but were markedly reduced at later stages of amyloid formation. Furthermore, IL-1Ra release from human islets was reduced during 7-day culture in a time-dependent manner. These changes in IL-1Ra production and release from human islets during amyloid formation adversely correlated with islet IL-1β levels, β-cell Fas expression and apoptosis. Treatment with IL-1β neutralizing antibody markedly reduced amyloid-induced β-cell Fas expression and apoptosis, thereby improving islet β-cell survival and function during culture.

Conclusions: These data suggest that amyloid formation impairs the balance between IL-1β and IL-1Ra in islets by increasing IL-1β production and reducing IL-1Ra levels thereby promoting β-cell dysfunction and death. Restoring the IL-1β/IL-1Ra ratio may provide an effective strategy to protect islet β-cells from amyloid toxicity in T2D.

Keywords: Amylin; BSA, bovine serum albumin; ER, endoplasmic reticulum; FBS, fetal bovine serum; IL-1R1, IL-1 receptor type I; IL-1Ra, IL-1 receptor antagonist; IL-1β, interleukin-1β; Interleukin-1 receptor antagonist; Interleukin-1β; Islet amyloid; Islet amyloid polypeptide; Islet inflammation; KRB, Krebs–Ringer bicarbonate; PFA, paraformaldehyde; T2D, type 2 diabetes; Type 2 diabetes; hIAPP, human islet amyloid polypeptide; nIL1β, neutralizing IL-1β; rIAPP, rat islet amyloid polypeptide; β-cell apoptosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Amyloid / metabolism*
  • Animals
  • Apoptosis*
  • Caspase 8 / metabolism
  • Cell Line
  • Cells, Cultured
  • Fas Ligand Protein / metabolism
  • Humans
  • Insulin-Secreting Cells / drug effects
  • Insulin-Secreting Cells / metabolism*
  • Interleukin 1 Receptor Antagonist Protein / metabolism*
  • Interleukin-1beta / metabolism*
  • Mice
  • Middle Aged

Substances

  • Amyloid
  • Fas Ligand Protein
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1beta
  • Caspase 8

Grants and funding